Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
MARGetuximab Or Trastuzumab (MARGOT)
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT04425018
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Brigham Cancer Center - Foxborough, Foxboro, Massachusetts, United States
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT04419181
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 216
- Registration Number
- NCT04398914
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Target Recruit Count
- 493
- Registration Number
- NCT04337658
- Locations
- 🇨🇳
Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 15
- Registration Number
- NCT04253561
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain
🇪🇸Hospital Universitario del Vall d' Hebron, Barcelona, Spain
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04208178
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of California LA, Los Angeles, California, United States
🇪🇸Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1560
- Registration Number
- NCT04193059
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT04188548
- Locations
- 🇺🇸
Winship Cancer Center Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT04172259
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2907
- Registration Number
- NCT04158258
- Locations
- 🇦🇷
Instituto Alexander Fleming, Buenos Aires, Argentina
🇦🇷Instituto de Oncología de Rosario, Rosario, Argentina
🇦🇷Sanatorio de la Mujer, Rosario, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.